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Abstract
Summary This study explores bone marrow function in patients
with defective WNT1 signaling. Bone marrow samples showed
increased reticulin and altered granulopoiesis while overall he-
matopoiesis was normal. Findings did not associate with severity
of osteoporosis. These observations provide new insight into the
role of WNT signaling in bone marrow homeostasis.
Introduction WNT signaling regulates bone homeostasis and
survival and self-renewal of hematopoietic stem cells.
Aberrant activation may lead to osteoporosis and bone mar-
row pathology. We aimed to explore bone marrow findings in
a large family with early-onset osteoporosis due to a hetero-
zygous WNT1 mutation.
Methods We analyzed peripheral blood samples, and bone
marrow aspirates and biopsies from 10 subjects with WNT1
mutation p.C218G. One subject was previously diagnosed
with idiopathic myelofibrosis and others had no previously
diagnosed hematologic disorders. The findings were correlat-
ed with the skeletal phenotype, as evaluated by number of
peripheral and spinal fractures and bone mineral density.
Results Peripheral blood samples showed no abnormalities in
cell counts, morphology or distributions but mild increase in
platelet count. Bone marrow aspirates (from 8/10 subjects)
showed mild decrease in bone marrow iron storages in 6 and
variation in cell distributions in 5 subjects. Bone marrow bi-
opsies (from 6/10 subjects) showed increased bone marrow
reticulin (grade MF-2 in the myelofibrosis subject and grade
MF-1 in 4 others), and an increase in overall, and a shift
towards early-phase, granulopoiesis. The bone marrow find-
ings did not associate with the severity of skeletal phenotype.
Conclusions Defective WNT signaling associates with a mild
increase in bone marrow reticulin and may predispose to
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myelofibrosis, while overall hematopoiesis and peripheral
blood values are unaltered in individuals with a WNT1 muta-
tion. In this family with WNT1 osteoporosis, bone marrow
findings were not related to the severity of osteoporosis.
Keywords Hematopoiesis . Hematopoietic stem cells .
Myelofibrosis . Osteoporosis .WNTsignaling
Introduction
WNT signaling has an important role in bone health.
Abnormal WNT signaling can lead to several skeletal disor-
ders with reduced (e.g., osteoporosis-pseudoglioma syn-
drome, early-onset osteoporosis) or increased (van Buchem
disease and sclerosteosis) bone mass [1–4]. We and others
previously identified WNT1 as the key ligand for the WNT/
β-catenin pathway in bone and showed that loss-of-function
WNT1 mutations lead to severe early-onset osteoporosis [5,
6]. In mice,Wnt1 was expressed in bonemarrow, especially in
the B cell lineage and hematopoietic progenitors; lineage trac-
ing identified expression of the gene in a subset of osteocytes,
suggesting that altered cross-talk between the hematopoietic
and osteoblastic lineage cells may play a role in the pathogen-
esis of WNT1 osteoporosis [5]. However, the role of WNT
signaling and effects of WNT1 mutations on bone marrow
homeostasis remain unclear.
WNT signaling is an important mediator in hematopoiesis
and maintenance of bone marrow homeostasis. WNTs are
essential for survival of hematopoietic stem cells (HSCs) as
they regulate the renewal and quiescence of primitive HSCs
and stimulate their proliferation and progression towards
lineage-specific-committed progenitor cells. [7–11]
Prolonged WNT/β-catenin stimulus, on the other hand, may
prevent HSCs from their ability to repopulate and differentiate
properly, which may ultimately lead to bone marrow failure
[12]. WNT signaling may also predispose to bone marrow
pathology; it is dysregulated in myeloproliferative neoplasms
and disorders [13, 14] and communicates with other bone
marrow pathology -related factors, such as transforming
growth factor beta (TGF-β) [15]. The exact role of WNT
signaling, the key WNT ligands, and the coactivators or in-
hibitors participating in hematopoietic homeostasis, however,
remain yet to be established.
Our initial studies on WNT1 concerned a large Finnish
family with early-onset osteoporosis due to a heterozygous
missense mutation p.C218G in WNT1 [5]. The mutated
WNT1 leads to reduced WNT/β-catenin-signaling and low
osteoblastic function, low bone mass and fractures in children
and adolescents, and to severe osteoporosis in adults [5, 16].
One of our WNT1 mutation-positive subjects was diagnosed
with idiopathic primary myelofibrosis (PMF) and some other
family members reported a history of anemia. Considering the
interactions between bone tissue and bone marrow and the
importance of WNT signaling therein [17], and expression
of WNT1 in bone marrow [5], we hypothesized that defective
WNT1 signaling would cause changes in bone marrow and
hematopoiesis in WNT1 mutation-positive individuals.
Materials and methods
Subjects
Our index family includes 20 family members with a heterozy-
gous WNT1 missense mutation c.652T>G (p.C218G) [5, 16].
All have been carefully phenotyped for skeletal features, as
reported previously [14, 16, 18], by dual-energy X-ray absorp-
tiometry (DXA), spinal radiography and/or spinal magnetic
resonance imaging (MRI). We offered all mutation-positive
adults an opportunity to participate in further studies concerning
the characteristic of WNT1 osteoporosis, including hematolog-
ic and bonemarrow features. Nine subjects consented and com-
prised the study cohort (hereafter: COHORT). For the family
member with diagnosed PMF (hereafter: INDEX), we collected
and reanalyzed previously obtained clinical, hematologic and
PMF treatment -related data, including bone marrow samples.
We also inquired about dietary habits and possible dietary re-
strictions. The studywas approved by the Institutional Research
Ethics Board. All study subjects gave their written informed
consent before participation.
Genetic evaluations
Weperformed genetic validations onDNA fromperipheral blood
as previously described [16]. The presence of the heterozygous
mutation c.652T>G (p.C218G) in WNT1 (National Center for
Biotechnology Information [NCBI] Reference Sequence
[RefSeq], NM_005430.3) was confirmed in all participants.
Biochemical and hematologic evaluations
We obtained peripheral blood samples for the COHORT and
assessed them for complete blood count with differential, pa-
rameters of calcium, phosphate, and iron homeostasis, hemo-
globin isoelectric focusing, and peripheral blood cell morphol-
ogy. For the INDEX, we used the peripheral blood sample
results obtained at the time of PMF diagnosis. We compared
results with the NordLab reference values and report them ac-
cording to the general guidelines formed by the International
Council for Standardization in Hematology (ICSH) [19].
Bone marrow samples
We obtained bone marrow aspirate and biopsy samples ac-
cording to normal protocols in local anesthesia from posterior
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iliac crest with a standard aspirate and trephine needles. Due to
technical or patient-related reasons, reliable bone marrow as-
pirate and biopsy samples were not obtained for all and were
available for 7/9 and 5/9 subjects in the COHORT, respective-
ly. For the INDEX, we re-examined bone marrow samples
obtained at the time of PMF diagnosis in 2010 simultaneously
with the other samples. All aspirate samples were first
reviewed by a laboratory hematologist at NordLab at the
Oulu University Hospital. Aspirate and biopsy samples were
then reviewed by an experienced hematopathologist (P.E.K.)
at the Department of Pathology (HUSLAB), Helsinki
University Hospital, who was blinded to the subjects’ clinical
status and diagnosis.
Bone marrow aspirate samples were assessed for overall
quality, cellularity and cell type distribution. As advised by
International Council for Standardization in Hematology
(ICSH), at least 500 cells were counted from each sample to
obtain precise percentages [19]. All results are reported ac-
cording to the ICSH guidelines for the standardization of bone
marrow specimens and reports [19].
Bone marrow core biopsy samples were assessed for over-
all microscopic microarchitecture, cellularity, and cell mor-
phology using hematoxylin and eosin staining for cell mor-
phology, chloroacetate esterase for granulocytic lineage, CD3-
and CD20-staining for lymphocyte immunohistochemistry,
periodic acid-Schiff staining for polysaccharides and reticulin
staining for fibrosis. The amount of reticulin (marrow fibrosis,
MF) was graded MF0–3 according to the European
Consensus on grading of bone marrow fibrosis [20]; MF-0,
scattered linear fibers with no intersections;MF-1, loose fibers
with many intersections; MF-2, diffuse and dense increase
with extensive intersections; MF-3, as in MF-2 but also with
coarse bundles of collagen. All results are presented according
to the ICSH guidelines for bonemarrow samples [21]. Giemsa
staining was used for G-band analysis of chromosomes.
Correlations with skeletal features
We collected fracture histories, BMD data and radiological
data from spinal imaging, and compared the findings with
bone marrow findings. We classified each of the skeletal and
bone marrow parameters into three categories of increasing
severity to evaluate the possible associations between bone
marrow findings and skeletal changes, osteoporosis treatment,
gender and subject’s age.
Results
Cohort characteristic
In addition to the INDEX, an adult female with PMF, the
study COHORT included six females and three males from
the same family (age range 33–76 years, median age 45 years)
with varying severity of skeletal changes (Table 1,
Supplemental Fig. 1). Out of the whole cohort of 10 subjects,
5 had prior or on-going osteoporosis medication at the time of
the study. None received iron supplementation. All followed a
normal diet and none had any specific dietary restrictions at
the time of the study.
Findings in the INDEX with WNT1 mutation
and myelofibrosis
The 39-year-old female (AIII-1, Fig. 1) was diagnosed with
osteoporosis in 2006; a disease-causing heterozygous WNT1
mutation was confirmed. She had a history of four peripheral
fractures, three vertebral compression fractures on spinal ra-
diographs and only osteopenic BMD (Table 1). Osteoporosis
medication was not initiated. Four years later, routine control
tests indicated elevated liver enzymes: alanine transaminase
(ALT) 169 U/L (normal < 35 U/L), aspartate transaminase
(AST) 55 U/L (normal range 15–35 U/L), alkaline phospha-
tase (ALP) 225 U/L (normal range 35–105 U/L), and
glutamyltransferase (GT) 208 (normal < 40 U/L). An abdom-
inal ultrasound revealed a large thrombus obstructing the por-
tal vein and extending into the lienal and superior mesenteric
veins. Abdominal CT and MRI showed a pathologic liver
structure and slight splenomegaly. Blood samples revealed
mild thrombocytosis (634 × 109/L), prolonged prothrombin
time, and slightly increased lactase dehydrogenase while he-
moglobin, leukocytes and erythrocyte parameters were nor-
mal (Supplemental Table 1). A bone marrow aspirate showed
fibrotic and firm bone marrow fragments and an increased
number of clustered and morphologically abnormal megakar-
yocytes (Table 2). A trephine biopsy from iliac crest con-
firmed megakaryocyte hyperplasia and increased fibrosis;
sample showed extensive increase in reticulin (MF-2) and
clusters of large megakaryocytes (Table 3 and Fig. 1a). Bone
marrow cell culture with mononuclear stem cells showed no
spontaneous erythrocyte or megakaryocyte proliferation.
Genetic studies for the Janus Kinase 2 (JAK2) mutation and
chromosomal studies for Philadelphia-chromosomewere neg-
ative and a diagnosis of idiopathic myelofibrosis was set.
Interferon treatment was not commenced, as she remained
stable during follow-up.
Findings in the COHORTwith WNT1 mutation
In peripheral blood samples obtained from nine other family
members without known hematologic pathology, no signifi-
cant changes were detected; complete blood count showed
normal hemoglobin in all but one subject who had mild ane-
mia, and normal erythrocyte and leukocyte counts
(Supplemental Table 1). Platelet count was elevated in one.
Differential leukocyte count showed overall normal
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distribution in all subjects but one had mild neutropenia and
one, lymphopenia. Microscopy of peripheral blood cells
showed no abnormalities. EPO was normal in all. Ferritin
was low in one subject and elevated in three. Lactase dehy-
drogenase was elevated in two subjects. Calcium and phos-
phate concentrations were low in two subjects, and parathy-
roid hormone and ALP levels were slightly increased in one
and two subjects, respectively (Supplemental Table 1).
Bone marrow aspirates were obtained from seven of the
nine subjects in the COHORT (Table 2). In general, the sam-
ples had normal cellularity and cellular morphology in all
subjects and there were no signs of increased precursor cells.
Megakaryocytes and lymphocytes were normal in amount and
morphology while one subject (AIII-2) had some megakaryo-
cytes with over-lobulated and fragmented nuclei, similar to the
INDEX. Four were low in storage iron and two had a reduced
number of sideroblasts. No infiltrates of abnormal or malig-
nant cells were seen in any of the samples.
Bone marrow core biopsies were obtained from five sub-
jects in the COHORT (Table 3, Figs. 1 and 2). The size of the
biopsies ranged from 15 to 20 mm and the area covered by
hematopoietic cells ranged from 50 to 70%. Four biopsies had
increased and shifted towards early-phase granulopoiesis
(Fig. 2a). Two subjects had small infiltrates of reactive lym-
phocytes as assessed by immunostainings. Three subjects had
minor eosinophilia (Fig. 2b). All subjects had normal chromo-
some number, correct sex chromosomes and no signs of clonal
chromosome changes upon Giemsa G-band staining.
The core biopsies showed increase in reticulin fiber in four
of the five subjects (Table 3, Figs. 1b, c). In one of the five
biopsies, technical issues prevented assessment of reticulin
and hence reticulin was increased in all samples that could
Fig. 1 Iliac bone marrow
biopsies from three adult subjects
with heterozygous p.C218G
WNT1 mutation. a The 39-year-
old female INDEX (AIII-1) with
diagnosed myelofibrosis. Two
COHORT subjects, b a 33-year-
old female (AIII-2) and c a 62-
year-old male (AII-1).
Microscopic findings show in all
an increase in bone marrow
reticulin (arrows). ×400
resolution
Table 1 Clinical findings in 10 adults with a heterozygous p.C218G WNT1 mutation
Subject (sex, age in years) F, 39* F, 33 F, 43 F, 51 M, 51 F, 52 M, 62 F, 70 F, 73 M, 75
Pedigree code AIII-1* AIII-2 AIII-5 AIII-6 AIII-4 AIII-3 AII-1 AII-2 AII-3 AII-4
Peripheral fractures 5 2 0 0 2 0 3 9 6 1
VCFs 3 0 0 0 3 6 7 8 9 5
BMD LS − 1.6 − 1.5 − 1.4 N/A − 2.8 − 2.0 − 2.2 − 1.5 − 0.8 0.5
BMD Fem neck − 1.7 − 2.2 − 0.9 N/A − 1.3 − 0.8 − 1.3 − 1.6 − 1.6 0.1
Prior osteoporosis medication N N N N N/A Y* Y Y Y* Y
VCF = vertebral compression fractures; ≥ 20% decrease in vertebral height. BMD= bone mineral density; measured with dual-energy X-ray absorpti-
ometry, values converted to age- and gender-adjusted Z-scores. LS = lumbar spine. Fem = femoral. Y = yes; N = no; N/A = not available; * = bisphos-
phonate treatment on-going at the time of the study
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Table 2 Bone marrow aspirate
findings in 8 adults with a
heterozygous p.C218G WNT1
mutation
Subject (sex, age in years) F, 39* F, 33 F, 43 F, 51 M, 51 F, 52 M, 62 M, 75
Pedigree code AIII-1* AIII-2 AIII-5 AIII-6 AIII-4 AIII-3 AII-1 AII-4
Cellularity N N N N N N N N
Blasts (%) N 0.8 0.2 1.6 0.4 1.1 N/A N/A
Megakaryocytes I N N N N N N N
Promyelocytes (%) N/A 2.6 3.4 1.4 1.5 4.3 N/A N/A
Myelocytes (%) N/A 25.4 22.1 18.0 18.4 23.1 N/A N/A
Metamyelocytes
and bands (%)
N/A 18.3 15.5 12.3 10.7 10.1 N N
Neutrophils (%) N 20.9 17.0 21.4 16.2 18.2 N N
Eosinophils, early (%) N 0.2 0.2 1.0 1.0 4.7 N N
Basophils (%) N 0 0 0.6 0 0 N N
Monocytes (%) N 0.4 0.9 0.8 0.2 0.2 N/A N/A
Pronormoblasts (%) N/A 0.2 0.2 0.6 0.2 0.2 N/A N/A
Basophilics (%) N 0.6 1.7 2.0 0.4 0.9 N N
Polychromatics (%) N/A 13.8 10.5 18.4 14.9 8.1 N/A N/A
Orthochromatics (%) N/A 4.7 6.2 6.5 17.3 11.6 N/A N/A
Lymphocytes (%) I 11.2 20.2 13.5 14.2 12.4 N N
Plasmacells (%) N 0.4 1.1 0.2 2.7 1.3 N N
Histiocytes N N N N N N N N
Mast cells N N N N N N N N
Iron storage +/− – – – ++ + ++ +
Sideroblasts + N/A – + + + N/A −/+
The INDEX subject with diagnosed primary myelofibrosis indicated with an asterisk (AIII-1). Supranormal
values are underlined and subnormal values are in italics. Normal ranges according Wintrobe’s Clinical
Hematology 11th ed [22]
N normal, I increased
Table 3 Bone marrow biopsy
findings in 6 adults with a
heterozygous p.C218G WNT1
mutation
Pedigree code AIII-1* AIII-2 AIII-5 AIII-6 AII-1 AII-4
Cellularity (%) 65 70 55 55 50 50
Reticulin (0–3) 2 1 1 N/A 1 1
Megakaryocytes (N/I/D) I N N N N N
Megakaryocyte morphology Hyperlobulation; large,
dispersed, clusters
N N N N N
Granulopoiesis (%) 60 55 50 50 60 60
Granulopoiesis (%. early:late) 55:45 50:50 60:40 50:50 50:50 30:70
Granulopoiesis (N/I/D) I++ I+ I+ I+ I+ N
Erythropoiesis (%) 30 25 30 35 30 20
Erythropoiesis (normal:early) Early+ N N N N N
Lymphocytes 10 20 10 15 10 10
Lymphocytes 3 1 2 0 1 2
Eosinophils < 5 < 5 10 < 5 5 10
Plasma cells (N/I/D) N N N N N N
Blasts (N/I/D) N N N N N N
Histiocytes (N/I/D) N N N N N N
The INDEX subject with diagnosed primary myelofibrosis indicated with an asterisk (AIII-1). Supranormal
values are underlined and subnormal values are in italics. Normal ranges according Wintrobe’s Clinical
Hematology 11th ed [22]
N normal, I increased, D decreased
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be properly analyzed. These changes were mild and classified
as gradeMF-1 (on scale 0–3) in the four subjects, as compared
with the grade MF-2 in the INDEX with PMF. The amount of
marrow reticulin did not associate with age, sex or menopaus-
al status as these four COHORT subjects ranged in age from
33 to 75 years and represented both sexes. Like the INDEX,
these four subjects also had increased and shifted towards
early-phase granulopoiesis. In two subjects, bone marrow iron
storages were depleted with a low number of sideroblasts. The
overall marrow cellularity was only increased in one
COHORT subject (AIII-2), and megakaryocyte morphology
and erythropoiesis were normal.
Association between skeletal and bone marrow findings
The INDEX (AIII-1) with the most severe bone marrow fibro-
sis had a relatively mild skeletal phenotype with osteopenia
and three spinal fractures (Table 1, Fig. 3a). The four other
subjects with mild increase in bone marrow fibrosis had var-
iable skeletal pathologies; two of them had no spinal compres-
sion fractures and only osteopenic BMD, while two of them
had significant skeletal changes with several compression
fractures (Table 1, Fig. 3b–d). Overall, there was no
association between the bone marrow findings and the sever-
ity of osteoporosis as evaluated from the number of fractures
and bonemineral density (Supplemental Fig. 2). Further, bone
marrow changes were not related to age. Two subjects with
bone marrow fibrosis, as well as the INDEX, were naïve to
any osteoporosis medication.
Discussion
This is the first study to report bone marrow findings in adult
subjects with impaired WNT signaling; all 10 evaluated indi-
viduals harbored a heterozygousWNT1mutation. Our INDEX
subject was diagnosed with primary myelofibrosis while the
nine other subjects had no previously diagnosed hematologic
diseases. In line with our hypothesis, four COHORTsubjects—
all whose bone marrow biopsy could be properly evaluated—
presented with slightly increased bone marrow reticulin.
Peripheral blood profiles in the nine COHORT subjects were
similar to those of the INDEX (e.g., normal hemoglobin levels,
platelet counts close to the upper normal limit, and leukocyte
counts close to the lower normal limit) and a shift towards
early-phase granulopoiesis. Bone marrow findings did not as-
sociate with severity of skeletal phenotype.
Diffuse bone marrow reticulin is not seen in healthy indi-
viduals. Therefore, it is reasonable to hypothesize that aberrant
WNT1 signaling due to the WNT1 mutation underlies in-
creased reticulin formation in our study COHORT and prima-
ry myelofibrosis in our INDEX. While WNTs’ role in bone
marrow fibrosis remains underdetermined, recent studies have
shown that β-catenin induces bone marrow fibrosis indirectly
through fibrocytic and immunoregulatory responses [23], that
canonical WNT/β-catenin pathway is dysregulated in PMF
[7], and that β-catenin expression is increased in PMF [24].
Furthermore, it is known that there lies direct crosstalk and
positive feedback between TGF-β, an activator of fibroblast
collagen synthesis and inducer of marrow fibrosis [25], and
WNT signaling [9]. Also of note, WNT signaling is known to
contribute to several other fibrotic diseases involving such
tissues as the lungs, kidneys, and heart [26–28].
Our main aim was to study whether the WNT1 mutation
p.C218G causes increased bone marrow fibrosis and would be
linked to the PMF diagnosed in one of our subjects with WNT1
osteoporosis. Myelofibrosis is a malignant myeloproliferative
disorder with neoplastic clonal proliferation of a single
multipotent hematopoietic stem cell. Common clinical features
include severe anemia, mild leukopenia, thrombocytosis, and
splenomegaly, and bone marrow biopsies portray a pathologic
population ofmegakaryocytes, an increase in reticular fibers and,
at later stages, collagen fibrosis (osteosclerosis) [29, 30].
Majority of MF patients have a mutation in JAK2, MPL, or
CALR [30–34]. Altogether, 60% of primary myelofibrosis cases
are caused by a dominant, gain-of-function p.V617Fmutation in
Fig. 2 Iliac bone marrow biopsy from two adults with a heterozygous
p.C218G WNT1 mutation. a A 43-year-old female subject (AIII-5),
microscopic findings show increase in early phase granulopoiesis
(examples of chloroacetate esterase (leder)-positive myelocytes indicated
by arrows). b A 75-year-old male subject (AII-4), microscopic findings
show mild eosinophilia (arrows) (H&E-staining). ×100 resolution
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JAK2, which is known to cause also a large portion of polycy-
themia vera and essential thrombocytosis cases [30–34]. While
the JAK2mutation was excluded in our INDEX, no studies were
performed for possibleMPL orCALR variations. However, bone
marrow stem cell cultures indicated no spontaneous
myeloproliferation typically observed in MPL- and CALR-posi-
tive cases, suggesting that theWNT1mutation could account for
our INDEX subject’s findings.
Mature osteoblasts partake in accommodating HSCs in the
osteoblastic bone marrow niche near endosteum and WNTsig-
naling directly participates in the niche-mediated regulation of
HSC maintenance and differentiation [35, 36]. Certain WNT
ligands are specifically expressed in bone marrow and regulate
hematopoiesis. Luis et al. have hypothesized that WNT3a
would solely carry this function as it nonredundantly regulates
HSC function and lack of its stimulus results in complete ab-
sence of WNT signaling. However, WNT5A and WNT11 sig-
nal through noncanonical WNT pathways and also assist in
hematopoietic processes [37–39]. Our findings indicate that
WNT1 may play a role in maintenance of the hematopoietic
niche and regulation of stem cells. Of note, the severity of oste-
oporosis or prior or on-going osteoporosis medication did not
seem to impact the hematologic bone marrow findings. Also,
there are no reports of myelofibrosis, other bone marrow chang-
es, or severe hematologic abnormalities in individuals with ho-
mozygous WNT1 mutations. These together indicate that the
changes in bone marrow are independent and not secondary to
the changes in adjacent trabecular and cortical bone tissue and,
hence, a direct consequence of aberrant WNT1 signaling.
Besides reticulin formation, other mild changes were also
seen that underscore the role of aberrant WNTsignaling in bone
marrow pathology. Firstly, three subjects in our COHORT pre-
sented with low iron storage and four subjects with a reduced
sideroblast number. In the INDEXwith PMF, iron storages were
low but sideroblasts were visible. Many malignant processes of
the bone marrow can hamper iron storages; leukemia and other
proliferative conditions displace erythropoietic cells and cause
diminished iron stores [40] and, while bone marrow smears
may show low sideroblasts and deplete iron storages, peripheral
blood concentrations of hemoglobin and iron may remain nor-
mal [41]. Secondly, two subjects had mild eosinophilia.
Although causes of eosinophilia are numerous, both primary
and secondary, several studies have characterized eosinophils
as a part of the malignant clone in myeloid neoplasms and my-
eloproliferative diseases arising from mutated multipotent mye-
loid stem cells [42–44], which supports the possibility that inef-
fective WNT signaling could give rise to the mild eosinophilia
through inadequate stem cell differentiation. However, there was
no eosinophilia in the PMF subject and therefore its connection
to aberrant WNT signaling remains to be studied.
Our study does have limitations primarily concerning the
cohort size. A greater number of samples from all age groups
would provide more sound and reliable results and perhaps
reveal minor systematic changes that now escaped our atten-
tion. However, bonemarrow biopsy, as an invasive procedure,
can be difficult to obtain due to either subject- or ethics-related
restrictions. Our study is the first of its kind and therefore,
despite the limited cohort size, the results are important and
require validation in other cohorts. In addition, the WNT1
point mutation p.C218G causes a decrease in but not a com-
plete disruption of WNT signaling, which may explain why
our findings are quite subtle. There are also other WNT li-
gands that activate WNT signaling in bone and bone marrow
and they could partially alleviate the effects of decreased
WNT1 activity. Future studies could explore the expression
levels of b-catenin in peripheral blood or bone marrow biop-
sies from WNT1 mutation-positive subjects, which we were
unable to evaluate in the scope of this study. Despite these
Fig. 3 Spinal radiographs and
magnetic resonance images of
four subjects with a heterozygous
p.C218G WNT1 mutation and
bone marrow fibrosis. a The 39-
year-old female INDEX (AIII-1)
with diagnosed myelofibrosis.
Three COHORT subjects, b a 33-
year-old female (AIII-2), c a 43-
year-old female (AIII-5), and d a
62-year-old male (AII-1)
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restrictions, WNT1 mutations have only been described in a
handful of families worldwide and we therefore regard our
data rare and unique.
In conclusion, aberrant WNT1 signaling due to the hetero-
zygous p.C218G mutation in WNT1 causes a mild increase in
bone marrow reticulin that could be related to primary myelo-
fibrosis but other bone marrow changes are mild and variable.
The bone marrow findings did not associate with the severity of
osteoporosis phenotype. Our study provides exceptional and
valuable data on bone marrow changes in impaired WNT1
signaling. As new osteoporosis therapies targeting the WNT
signaling pathway are in development, a thorough understand-
ing of the clinically significant effects of the signaling pathway
in extra-skeletal tissues is important also for the growing pop-
ulation receiving medical treatment for osteoporosis.
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